From Cycle to
Cardiometabolic Health

As an OB-GYN, I'm seeing more patients wearing devices that quietly track their sleep, activity, temperature trends, and heart rate. Continuous, objective data has the power to support how OB-GYNs practice. Instead of relying only on a patient's recollection of bleeding and symptoms over the last year, you can now see summaries of cycle patterns between visits.

For people who menstruate, are trying to conceive, are pregnant, or are navigating perimenopause, those longitudinal signals have the potential to tell when something has shifted before it shows up in a chart note or lab value. Oura members wear the ring an average of 23.5 hours per day, generating near-continuous biometric data.

What follows describes what Oura actually measures, what's been validated, how those signals map to clinical questions across the reproductive lifespan, and how you might use or interpret these data at the point of care.

Oura Ring 4 is a lightweight, durable smart ring worn continuously, with 5–8 days of battery life. It tracks 50+ health insights using infrared PPG for heart rate and HRV, a peripheral skin temperature sensor reading approximately once per minute, an accelerometer for movement and sleep staging, and SpO2 sensing.

The arterial flow of the digits provides a strong PPG signal with advantages over sensors worn in other locations, and provides very high agreement between the ring and ECG, supporting high accuracy for nocturnal HR and heart rate variability (HRV). Members can download structured, exportable data summaries (e.g., cycle data) that turn vague recall into a concrete starting point for collecting a patient history.

Cycle Insights uses physiological data influenced by hormonal fluctuations — heart rate, HRV, temperature trends, and respiratory rate — to identify the follicular and luteal phases, label the day of ovulation, and predict period start date within a six-day window.

Oura Ring successfully detected ovulation in 96.4% of cycles, with 87.9% of detections occurring within 2 days and 68% within 1 day of the ovulation date; positive LH test results served as the benchmark reference. In comparison, the calendar method detected only 66.5% of ovulations within 3 days, 50.7% within 2 days, and 32.2% within 1 day. The mean absolute error (MAE) for Oura Ring was 1.26 days compared to 3.44 days for the calendar method — narrowing the ovulation window from approximately 7 days (calendar method) to 2.5 days (Oura Ring).

Cycle Insights now includes support for members using hormonal contraception. Members select from all available hormonal birth control methods — including oral contraceptives, patches, IUDs, and implants — and receive education contextualized to their specific method alongside their continuous biometric data. Because hormonal contraception alters temperature patterns, HRV, and other physiological signals that Cycle Insights relies on, this feature helps members recognize what is typical for them on their chosen method and flag deviations from that individual baseline. For clinicians, this means patients on hormonal contraception are less likely to misinterpret expected biometric shifts as a new health concern, and more likely to bring meaningful changes to your attention.

When a patient opts into Pregnancy Insights, Oura highlights key health metrics — including temperature trends, RHR, HRV, and respiratory rate — to illustrate physiological changes. These insights can help reassure patients as their personal biometric data is overlaid with population ranges to demonstrate the variation in vital sign changes. Pregnancy Insights includes educational content, gestational age tracking, and symptom tracking.

The Oura Perimenopause Report shows that women in late perimenopause tag substantially more symptoms than premenopausal women, and that HRV declines by roughly 20–30% over the perimenopausal transition, underscoring how physiologic strain accumulates across this life stage. Internal analyses from Oura's Perimenopause Report show substantial sleep loss for those in perimenopause compared to pre- and post-menopause.

Oura data cannot diagnose perimenopause or replace guideline-driven cardiovascular risk assessment, but it can flag meaningful deviations from a person's baseline — such as irregular menstrual cycle patterns or changes in sleep quality — and support earlier referral, more targeted work-ups, and more precise counseling around timing-sensitive topics like conception, perinatal stress, and care for perimenopausal symptoms.

Oura's Menopause Insights feature incorporates the Menopause Impact Scale, a scientifically validated clinical questionnaire that quantifies how perimenopausal symptoms are affecting a member's daily functioning. Rather than returning a score alone, the feature generates a personalized interpretation of results across contributing symptom domains and maps those responses to longitudinal biometric trends, including sleep continuity, HRV, and temperature patterns. Patients can arrive at visits with an objective, domain-level summary of symptom burden grounded in their own physiology rather than unstructured recall.

Oura's sleep staging algorithm has been validated against polysomnography (PSG), achieving 79% four-stage accuracy in adults and strong agreement for non-staging sleep metrics such as total sleep time and sleep efficiency. A Harvard-led validation study across multiple wearables found Oura Ring to be one of the most accurate devices tested for four-stage sleep classification compared with PSG.

Very high agreement between Oura Ring and ECG was observed for nightly average HR and HRV (r² = 0.996 and 0.980, respectively) in a 49-person lab validation. A multi-device comparison study also identified Oura as among the most accurate wearables for nocturnal resting heart rate (RHR) and HRV, with lowest errors and highest agreement level with ECG.